Treatment of BXSB- @entity27931 @entity19 with IL-21R-Fc fusion protein minimally attenuates XXXX .

@entity27931 @entity19 @entity1252 @entity1961 @entity6241 @entity792
@entity6241 ( @entity6241 ) is a pleiotropic cytokine whose function is only now being unraveled. Abundant evidence indicates that activated @entity1961 T cells are the primary, if not the only, source of @entity6241 . While it is clear that @entity6241 is actively transcribed by na  ve activated T cells, recent studies have shown that @entity6241 potentially promotes a developmental shift of na  ve T cells toward the Th2 phenotype. BXSB- @entity27931 @entity19 develop an @entity792 similar to @entity1252 ( @entity1252 ), affecting males earlier than females on account of the presence of the @entity27931 ( @entity27931 ) locus. Previous results indicate the elevation of @entity6241 expression by BXSB- @entity27931 @entity19 at an age when the early characteristics of autoimmune processes first become evident. We set out to determine whether @entity6241 was necessary for disease progression in BXSB- @entity27931 @entity19 . @entity19 were treated for 24 weeks with soluble IL-21R-Fc in order to therapeutically neutralize the @entity6241 present. The results overall suggest a biphasic effect of @entity6241 , negatively influencing survival early on and positively influencing survival at later stages. We propose that @entity6241 exerts a pleiotropic effect in which it promotes the protective effects of CD8+ suppressor cells in the early disease phase and then promotes the humoral components of @entity1252 in the later disease stages. This experiment provides preliminary evidence for a role of @entity6241 in modulating the severity of @entity1252 in BXSB- @entity27931 @entity19 .
